HOME >> BIOLOGY >> NEWS
New drug enfuvirtide shows promise against drug resistant HIV infection

CHAPEL HILL -- The new drug enfuvirtide, a member of a new class of medications designed to combat HIV -- the virus that causes AIDS -- shows strong promise in treating drug-resistant cases of the life-threatening infection, a study conducted with patients in North and South America concludes.

A report on the research appears in the May 29 issue of the New England Journal of Medicine.

"This is one of the most important studies performed to date in HIV-infected patients who have already received highly active antiretroviral therapy (HAART) and a landmark study for the field of HIV," said Dr. Joseph Eron of the University of North Carolina at Chapel Hill and a report author.

"The clinical work clearly demonstrates that a completely new class of anti-HIV medication, developed by a local company, Trimeris, is highly effective in a very large randomized study," said Eron, associate professor of medicine at the UNC School of Medicine.

"Enfuvirtide, or T-20, works by blocking HIV entry into CD4 + lymphocytes or T-cells and will benefit patients who already have HIV that is resistant to current therapy."

CD4+ lymphocytes, also known as T-cells, are a key part of the body's immune system for fighting off disease-causing viruses, bacteria and various other organisms, he said. HIV is so deadly because it kills those defenders and leaves patients vulnerable to a wide variety of debilitating illnesses.

Fuzeon is enfuvirtide's trade name.

Another report of a second study with similar results carried out in Europe and Australia also appears in the May 29 issue of the journal. Eron and Dr. J. Michael Kilby of the University of Alabama at Birmingham have a third article in the journal describing T-20 and other drugs now in development in the new class of HIV medications called entry inhibitors.

Dr. Jacob P. Lalezari of Quest Clinical Research, Mount Zion Hospital and the University of California at San Francisco led
'"/>

Contact: David Williamson
919-962-8596
University of North Carolina at Chapel Hill
28-May-2003


Page: 1 2 3

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... a product subsidiary of Infosys (NYSE: ... to integrate the Onegini mobile security platform with ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration will ... to access and transact across channels. Using this ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
Breaking Biology Technology:
Cached News: